Haemonetics Corp [HAE] stock is trading at $68.70, up 2.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HAE shares have gain 4.89% over the last week, with a monthly amount drifted -3.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Haemonetics Corp [NYSE: HAE] stock has seen the most recent analyst activity on February 07, 2025, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $68 from $95. Previously, JP Morgan started tracking the stock with Overweight rating on December 06, 2024, and set its price target to $116. On November 08, 2024, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $120 on the stock. CL King started tracking the stock assigning a Buy rating and suggested a price target of $116 on September 13, 2024. BofA Securities initiated its recommendation with a Neutral and recommended $85 as its price target on September 11, 2024. BTIG Research started tracking with a Buy rating for this stock on September 10, 2024, and assigned it a price target of $112. In a note dated June 12, 2024, Needham upgraded an Buy rating on this stock but restated the target price of $112.
Haemonetics Corp [HAE] stock has fluctuated between $58.80 and $97.97 over the past year. Currently, Wall Street analysts expect the stock to reach $107 within the next 12 months. Haemonetics Corp [NYSE: HAE] shares were valued at $68.70 at the most recent close of the market. An investor can expect a potential return of 55.75% based on the average HAE price forecast.
Analyzing the HAE fundamentals
Haemonetics Corp [NYSE:HAE] reported sales of 1.37B for the trailing twelve months, which represents a growth of 3.66%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.14 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.68 points at the first support level, and at 64.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.99, and for the 2nd resistance point, it is at 71.28.
Ratios To Look Out For
For context, Haemonetics Corp’s Current Ratio is 3.97. Also, the Quick Ratio is 2.55, while the Cash Ratio stands at 1.27. Considering the valuation of this stock, the price to sales ratio is 2.51, the price to book ratio is 3.81 and price to earnings (TTM) ratio is 27.04.
Transactions by insiders
Recent insider trading involved Lingamneni Anila, Former Officer, that happened on Nov 11 ’24 when 6238.0 shares were purchased. President, Global Hospital, Strong Stewart W completed a deal on Jul 26 ’24 to sell 4312.0 shares. Meanwhile, Officer Strong Stewart W bought 4312.0 shares on Jul 26 ’24.
